WOBURN, MA, United States

BioSense Technologies, Inc.

WOBURN, MA, United States
Time filter
Source Type

Ingawale M.,BioSense Technologies, Inc. | Dutta A.,George Mason University | Roy R.,Information Systems Management Institute | Seetharaman P.,Information Systems Management Institute
Online Information Review | Year: 2013

Purpose - Social media platforms allow near-unfettered creation and exchange of user generated content (UGC). Drawing from network science, the purpose of this paper is to examine whether high and low quality UGC differ in their connectivity structures in Wikipedia (which consists of interconnected user generated articles). Design/methodology/approach - Using Featured Articles as a proxy for high quality, a network analysis was undertaken of the revision history of six different language Wikipedias, to offer a network-centric explanation for the emergence of quality in UGC. Findings - The network structure of interactions between articles and contributors plays an important role in the emergence of quality. Specifically the analysis reveals that high-quality articles cluster in hubs that span structural holes. Research limitations/implications - The analysis does not capture the strength of interactions between articles and contributors. The implication of this limitation is that quality is viewed as a binary variable. Extensions to this research will relate strength of interactions to different levels of quality in UGC. Practical implications - The findings help harness the "wisdom of the crowds" effectively. Organisations should nurture users and articles at the structural hubs from an early stage. This can be done through appropriate design of collaborative knowledge systems and development of organisational policies to empower hubs. Originality/value - The network centric perspective on quality in UGC and the use of a dynamic modelling tool are novel. The paper is of value to researchers in the area of social computing and to practitioners implementing and maintaining such platforms in organisations. Copyright © 2013 Emerald Group Publishing Limited.

Zhao Z.,BioSense Technologies, Inc. | Chalmers A.,BioSense Technologies, Inc. | Rieder R.,BioSense Technologies, Inc.
Vox Sanguinis | Year: 2014

Background and Objectives: Current FDA-approved culture-based methods for the bacterial testing of platelet concentrate (PC) can yield false-negative results attributed to Poisson-limited sampling errors incurred near the time of collection that result in undetectable bacterial concentrations. Testing PC at the point of issue (POI) extends the incubation period for any contaminant bacteria increasing the probability of detection. Data are presented from time-course experiments designed to simulate POI testing of bacterially contaminated PCs at different stages of growth using differential impedance sensing. Study design and methods: Whole-blood-derived PCs were typically spiked with low numbers of bacteria (approximately 100 CFU/ml) and incubated under standard PC storage conditions. Each infected unit was evaluated every two hours over a 12-h period. All samples were treated with a chemical compound that induces stress in the bacterial cells only. The development of any bacterial stress was monitored by detecting changes in the dielectric properties of the PC using differential impedance. Results: Differential impedance measurements and corresponding cell counts at the different time-points are presented for six organisms implicated in post-transfusion-septic reactions. All infected PCs were detected once contaminant bacteria reached concentrations ranging between 0·6 × 103 and 6 × 103 CFU/ml irrespective of the phase of growth. Results were obtained within 30 min after the start of the assay and without the need for cell lysis or centrifugation. Conclusion: Differential impedance sensing can detect bacterial contamination in PC rapidly at concentrations below clinical thresholds known to cause adverse effects. © 2014 International Society of Blood Transfusion.

BACKGROUND: We have previously described a new rapid approach that relies on monitoring intentionally stressed bacteria in contaminated platelet concentrates (PCs). This earlier work included human cell lysis with Triton X-100 and filtration as steps in the sample preparation. This study was undertaken to develop an improved and time-saving protocol that enables direct bacterial detection in PCs without lysis and filtration. STUDY DESIGN AND METHODS: Apheresis- or whole blood-derived PCs were spiked with 17 model bacteria and tested at final concentrations from 103 to 10 6 colony-forming units (CFUs)/mL. The contaminated PCs were treated with a chemical compound that induces a stress response in bacteria and monitored using differential impedance sensing to detect and record subtle changes in the dielectric permittivities of the contaminated platelet (PLT) samples. RESULTS: No measurable responses from sterile PLT samples were observed during exposure to the compounds used as stressors. In contrast, distinct response profiles were obtained without exception for all 17 bacterial species for all bacterial concentrations tested. Bacterial presence was established within 5 to 10 minutes for high inocula (106 and 105 CFUs/mL) while low inocula (104 and 103 CFUs/mL) were usually detectable within 20 minutes. The entire testing process routinely took less than 30 minutes from the point of sampling to the time that the final results are available. CONCLUSIONS: The results described here demonstrate that monitoring the development of stress in bacteria is a fast and simple way to detect 103 CFUs/mL or more bacteria in complex cellular blood products such as PCs. © 2010 American Association of Blood Banks.

Zavizion B.,BioSense Technologies, Inc. | Zhao Z.,BioSense Technologies, Inc. | Nittayajarn A.,BioSense Technologies, Inc. | Rieder R.J.,BioSense Technologies, Inc.
PLoS ONE | Year: 2010

The ability to respond to adverse environments effectively along with the ability to reproduce are sine qua non conditions for all sustainable cellular forms of life. Given the availability of an appropriate sensing modality, the ubiquity and immediacy of the stress response could form the basis for a new approach for rapid biological testing. We have found that measuring the dielectric permittivity of a cellular suspension, an easily measurable electronic property, is an effective way to monitor the response of bacterial cells to adverse conditions continuously. The dielectric permittivity of susceptible and resistant strains of Escherichia coli and Staphylococcus aureus, treated with gentamicin and vancomycin, were measured directly using differential impedance sensing methods and expressed as the Normalized Impedance Response (NIR). These same strains were also heat-shocked and chemically stressed with Triton X-100 or H2O2. The NIR profiles obtained for antibiotic-treated susceptible organisms showed a strong and continuous decrease in value. In addition, the intensity of the NIR value decrease for susceptible cells varied in proportion to the amount of antibiotic added. Qualitatively similar profiles were found for the chemically treated and heat-shocked bacteria. In contrast, antibiotic-resistant cells showed no change in the NIR values in the presence of the drug to which it is resistant. The data presented here show that changes in the dielectric permittivity of a cell suspension are directly correlated with the development of a stress response as well as bacterial recovery from stressful conditions. The availability of a practical sensing modality capable of monitoring changes in the dielectric properties of stressed cells could have wide applications in areas ranging from the detection of bacterial infections in clinical specimens to antibiotic susceptibility testing and drug discovery. © 2010 Zavizion et al.

Mohamed S.,BioSense Technologies, Inc.
IET Conference Publications | Year: 2014

A point of care diagnosis system comprising of a smartphone and a method for reading the different reagent strips, that performs tests such as routine urinalysis, determining albumin to creatinine ratio and blood sugar tests based on reflectance photometry. uChek uses the camera sensor as an accurate image sensor, with the help of various image processing algorithms, to capture and perform various diagnostic tests. This system called uChek also pushes the data to a cloud database, to help monitor trends and track other useful data, making the results more accessible to labs, doctors and for demographic purposes. This system of diagnosis acts an alternative, affordable technology that not only makes the diagnosis a lot cheaper and suited to a low resource medical setup but also increases the usefulness of the data by recording seamlessly to a database and providing analysis, which helps in early detection and monitoring of treatment for various diseases.

Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 199.69K | Year: 2011

DESCRIPTION (provided by applicant): Resistance to chemotherapeutic drugs is an ongoing problem that results in eventual treatment failures or suboptimal patient outcomes. In cancer cells treated with drugs to which they are sensitive, the stress responseis the first step in the subsequent cascade leading to cell death (apoptotic, necrotic or autophagy). The recent availability of a sensing modality for monitoring the development of stress in viable cells makes possible the utilization of stress as a diagnostic tool. BioSense Technologies proposes the development of a new diagnostic assay to determine the chemosensitivity of BCR-ABL (+) leukemia cells to therapeutic agents in real-time using unprocessed blood or bone marrow samples. Because the initiation of the stress response is immediate, drug-resistant leukemia cells can be distinguished from drug-sensitive cells in real- time avoiding any need for traditional cell culture to obtain the same information. This ability to provide the most effective therapyfor each patient will reduce treatment failures and result in overall improved patient outcomes. Importantly, because the approach monitors a property fundamental to all cells, it is directly applicable to all other cancer cells types including solid tumor cancers. Feasibility of the proposed approach will be demonstrated with established human myeloid and lymphoblastic (Ph+) cell lines both drug-sensitive and -resistant to tyrosine kinase inhibitors. A follow-on effort will focus on the development of prototype instrumentation and validate the approach through clinical testing. PUBLIC HEALTH RELEVANCE: The development of a real-time diagnostic tool for determining the sensitivity/resistance profiles of leukemia cells to therapeutic agents is a significant step towards the administration of personalized medicine and optimal patient outcomes. By addressing and overcoming a significant technical barrier (the ability to determine the effects of a therapeutic agent on a cancer cell rapidly) the proposed project enables drug-resistant cancer cells to be distinguished from drug-sensitive cells in real-time. The availability of this diagnostic tool will arm oncologists with knowledge on the most effective drugs for eliminating the cancer cells as well as monitoring the possible onset of drug resistance during the administration of treatment. These new capabilities will avoid the empirical prescription of cancer therapy and enable the start or modification of existing treatment choices as needed. While the technical approach is applicable to a spectrum of different cancer types and therapeutic agents, this project focuses on the chemosensitivity testing of leukemia cells to tyrosine kinase inhibiting agents and the identification of drug resistance as an initialdemonstration of its feasibility.

Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 203.22K | Year: 2016

DESCRIPTION provided by applicant Infectious disease has now entered a post antibiotic era where multi drug resistance is increasingly common There is an immediate need for new diagnostics that can determine the susceptibility of pathogenic bacteria to antibiotics rapidly and accelerate the administration of targeted therapy for optimal patient outcomes BioSense Technologies proposes the development of a new phenotypic assay for determining antibiotic minimum inhibitory concentrations MIC in minutes The technology monitors the development of antibiotic induced cellular stress as an early response for determining the effect of therapeutic agents on cellular suspensions The immediacy and ubiquity of the response enables near real time assessment of all bacterial species treated with drugs having different mechanisms of action We propose to demonstrate feasibility of the approach by measuring the early responses of isolates spanning a wide range of MIC values for six organism antibiotic combinations to construct susceptibility response profiles and corresponding database The Phase I effort will conclude with a blinded study to validate the technical approach In Phase II additional organism antibiotic combinations will be studied including all important resistance mechanisms and platform hardware will be expanded to accommodate measurement of a larger number of therapeutic agents PUBLIC HEALTH RELEVANCE The treatment of infectious diseases has now entered the post antibiotic era where drug resistant infections are commonplace as our arsenal of effective therapies dwindles There is an immediate need for new technologies to identify drug resistance as quickly as possible to administer targeted therapies Existing automated antibiotic susceptibility testing systems have assay times of hours or more depending on the organism and next day turn around times delaying the administration of targeted therapy The successful development of the proposed near real time antibiotic susceptibility technology will address this public health crisis directly as part of a new generation of clinical microbiology laboratory diagnostics The ability to pair rapid AST results with rapid ID measurements having commensurate TAT such as the recent FDA approved MALTI TOF mass spectrometry systems would enable same day results and significantly impact the administration of inappropriate therapies and overall antibiotic stewardship

BioSense Technologies, Inc. | Entity website

BioSense Technologies, Inc. | Entity website

About BioSense Technologies BioSense Technologies is a privately held, early-stage biomedical company that develops technology for personalized medicine to treat cancer and infectious disease. The company is developing a proprietary new rapid platform technology to determine the chemosensitivity of difficult to culture cancer cells and antibiotic resistant infectious disease specimens ...

BioSense Technologies, Inc. | Entity website

Career Positions at BioSense Technologies Our company is seeking creative and energetic individuals to join our research and development teams.If you would like to be considered for a position at BioSense Technologies please send a cover letter and resume to: hr@biosensetech ...

Loading BioSense Technologies, Inc. collaborators
Loading BioSense Technologies, Inc. collaborators